Ascentage Pharma Group International (NASDAQ:AAPG) Coverage Initiated at B. Riley Financial

B. Riley Financial assumed coverage on shares of Ascentage Pharma Group International (NASDAQ:AAPG) in a report released on Wednesday. The brokerage set a “buy” rating and a $45.00 price target on the stock. B. Riley Financial’s price objective suggests a potential upside of 163.62% from the stock’s previous close.

Several other equities analysts also recently commented on AAPG. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Deutsche Bank Aktiengesellschaft began coverage on shares of Ascentage Pharma Group International in a report on Friday, April 24th. They issued a “buy” rating and a $40.00 target price on the stock. Finally, BTIG Research reissued a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a report on Monday, April 13th. Two equities research analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. According to MarketBeat.com, Ascentage Pharma Group International currently has a consensus rating of “Buy” and a consensus target price of $46.43.

Ascentage Pharma Group International Trading Down 0.3%

AAPG stock opened at $17.07 on Wednesday. Ascentage Pharma Group International has a one year low of $16.92 and a one year high of $48.45. The company’s fifty day moving average price is $22.53 and its 200-day moving average price is $24.99. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The firm had revenue of $24.72 million for the quarter. Research analysts forecast that Ascentage Pharma Group International will post -1.09 EPS for the current year.

Institutional Investors Weigh In On Ascentage Pharma Group International

A number of hedge funds have recently bought and sold shares of AAPG. XY Capital Ltd raised its stake in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares in the last quarter. UBS Group AG lifted its holdings in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares during the last quarter. Hsbc Holdings PLC bought a new position in shares of Ascentage Pharma Group International in the 2nd quarter valued at about $391,000. Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International in the 3rd quarter valued at about $383,000. Finally, ABC Arbitrage SA bought a new position in shares of Ascentage Pharma Group International in the 3rd quarter valued at about $204,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.